AN OPEN LABEL, MULTICENTER EXTENSION STUDY OF TRASTUZUMAB MCC DM1 (T-DM1) ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS PREVIOUSLY TREATED WITH THE EQUIVALENT T-DM1 REGIMEN IN A GENENTECH AND/OR F. HOFFMANN-